The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies
Ming-Li Zou1,2† Zhong-Hua Chen3† Ying-Ying Teng2 Si-Yu Liu1,2 Yuan Jia1,2 Kai-Wen Zhang1,2 Zi-Li Sun1,2 Jun-Jie Wu2 Zheng-Dong Yuan2 Yi Feng2 
Xia Li2* Rui-Sheng Xu2* 
Feng-Lai Yuan2*- 1Wuxi Clinical Medicine School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Wuxi, China
- 2Institute of Integrated Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, China
- 3Institute of Integrated Chinese and Western Medicine, The Third Hospital Affiliated to Nantong University, Wuxi, China
Bone remodeling is a continuous process that maintains the homeostasis of the skeletal system, and it depends on the homeostasis between bone-forming osteoblasts and bone-absorbing osteoclasts. A large number of studies have confirmed that the Smad signaling pathway is essential for the regulation of osteoblastic and osteoclastic differentiation during skeletal development, bone formation and bone homeostasis, suggesting a close relationship between Smad signaling and bone remodeling. It is known that Smads proteins are pivotal intracellular effectors for the members of the transforming growth factor-β (TGF-β) and bone morphogenetic proteins (BMP), acting as transcription factors. Smad mediates the signal transduction in TGF-β and BMP signaling pathway that affects both osteoblast and osteoclast functions, and therefore plays a critical role in the regulation of bone remodeling. Increasing studies have demonstrated that a number of Smad signaling regulators have potential functions in bone remodeling. Therefore, targeting Smad dependent TGF-β and BMP signaling pathway might be a novel and promising therapeutic strategy against osteoporosis. This article aims to review recent advances in this field, summarizing the influence of Smad on osteoblast and osteoclast function, together with Smad signaling regulators in bone remodeling. This will facilitate the understanding of Smad signaling pathway in bone biology and shed new light on the modulation and potential treatment for osteoporosis.
Introduction
Osteoporosis is a common systemic bone metabolism disorder characterized by decreased bone mass and disruption of the fine structure of bone tissue, which further results in increased bone fragility and occurrence of fracture (McGowan, 1993). Bone is a dynamic active tissue that needs to maintain the balance of bone mineralization and the integrity of bone structure through continuous remodeling (Lemaire et al., 2004). Continuous bone reconstruction is an important precondition of the preservation of bone health. Osteoclasts (OC) mediate the continuous absorption of bone matrix, followed by replacement of new bone by osteoblasts (OB). During bone remodeling, bone formation and bone resorption maintain a dynamic balance, which is called bone homeostasis (Kenkre and Bassett, 2018). Broken bone homeostasis would lead to osteoporosis. The mutual adjustment between OB and OC is the basis for maintaining bone homeostasis between bone formation and bone resorption. A variety of promising molecular signaling pathways are thought to be involved in this process, including MAPK, Wnt, Hedgehog, Notch, PI3K/Akt/mTOR, PDGF, IGF and Ca2+(Majidinia et al., 2018). It was previously shown that dysregulated Smad signaling pathway resulted in a number of bone disorders in humans (Liu et al., 2013).
The Smad protein family is an intracellular signaling protein identified in invertebrates by genetic screening methods in recent years (Ma and Meng, 2019). The name of Smad gene is a combination of the Drosophila gene ‘mothers against decapentaplegic' (Mad) and the Caenorhabditis elegans small protein (Sma) (Derynck et al., 1996). It has been shown that Smad protein is the key intermediates of canonical transforming growth factor-beta (TGF-β) signaling pathway and bone morphogenetic protein (BMP) pathway, which are important pathways that regulate bone homeostasis (Sánchez-Duffhues et al., 2015). It has been also suggested that Smad protein family and their activated downstream networks including the TGF-β pathway and the BMP pathway are concerned in cartilage development (Wang et al., 2020a). Therefore, understanding underlying Smad regulated molecular signaling pathways may profit the implications for osteoporosis. In this review, we attempted to shed light on recent studies of the effect of Smad signaling pathway in bone remodeling. Afterward we discuss the potential use of Smad for the treatment of osteoporosis.
Introduction of Smad Protein
Smad Protein
The Smad protein family is an intermediary molecule that transmits the signal generated by the binding of TGF-β and its receptor from the cytoplasm to the nucleus, thus playing an important role in signal transmission and regulating the transcription of downstream target genes (Luo, 2017).
Initially, through genetic screening of drosophila, it was discovered that the Mad polypeptide, which is downstream of the TGF-β family signaling pathway, has a highly conserved and unknown domain that was demonstrated to have high similarity with 3 types of peptides isolated from nematodes, cem-1, cem-2 and cem-3 (Sekelsky et al., 1995; Raftery and Sutherland, 1999). Since then, Mad has emerged as a new protein family. Then, through genetic screening in Caenorhabditis elegans, it was discovered that Sma-2, Sma-3 and Sma-4 all conserved domains that encode the same protein family at downstream of the TGF-β signaling pathway. The similarity of the structure and the connection with TGF-β family of Mad protein in drosophila and Sma protein in elegans attract people to homologous proteins in human, which was then named “Smad” in reference to its sequence similarity to the Sma and Mad proteins (Liu et al., 1996; Liu, 2003). And further studies also proved that Smad proteins act at downstream of serine/threonine kinase receptors (type I receptor and type II receptor), as well as Mad and Sma proteins (Urrutia et al., 2016).
Members of Smad Family
Up to now, 9 Smad members have been reported, which are called Smad 1- Smad 9 respectively. According to their structure and function, Smads can be divided into three categories. The first type are receptor-regulatory Smads (R-Smads) including Smad 1, 2, 3, 5, 8, 9, in which Smad 2 and Smad 3 are specific mediators of TGF-β or activin (Xu et al., 2003; Nakagawa et al., 2004; Li et al., 2011). They are phosphorylated between TGF-β and complexes formed between TGF-β type II receptors and activin receptor-like kinases ALK 4/5/7, or by activins and activin receptors 2, which participate in TGF-β and activin signaling pathways (Feng and Derynck, 2005; Katagiri and Tsukamoto, 2013). Complex formed by BMPs type I receptors ALK 1/2/3/6, BMPs type II receptors or activin receptors 2 could activate Smad 1, 5, 8 and possibly Smad 9, which is involved in conducting BMP signaling (Derynck and Zhang, 2003; Gomez-Puerto et al., 2019). Earlier studies have also confirmed that BMP-2/4 transmits signals via Smad 1, 5, and 8 (Zanotti et al., 2008; Song et al., 2011). The second type, the co-mediating Smad (Co-Smad), only one specie has been identified so far, namely the Smad 4. Smad 4 is like a central sensor, it can neither be phosphorylated nor bind to TGF-β receptors or BMP receptors. However, it can form heteromeric multimeric complexes with almost all activated R-Smads and therefore be able to participate in and regulate TGF-β signaling transduction (Wang et al., 2013). As Smad 4 has a proline-rich Smad 4 activiation domain (SAD) that regulates the interaction between transcriptional activation and inhibitory factors, which is necessary for transcriptional reactions that required for R-Smads activation (Kim and Jin, 2020). The third category is inhibitory Smads (I-Smads), with Smad 6 and Smad 7 included. In most resting cells, I-Smads are located in the nucleus. When stimulated by TGF-β or with overexpression of ubiquitination regulator Smurf 1, Smads 6 and 7 enter the cytoplasm from the nucleus (Chen et al., 2002). I-Smads bind to type I receptors, competitively interfere with recruitment and phosphorylation of R-Smads, and simultaneously inhibit the formation and activity of R-Smads and Co-Smad complexes (Kim and Jin, 2020). Smads 6, 7 can also interact with the ubiquitylated ligase Smurf E3, allowing it to bind to type I receptors, leading to receptor degradation to terminate signaling transduction (De Boeck and ten Dijke, 2012). I-Smads protein acts as a negative feedback signal for self-regulation of TGF-β signaling, as TGF-β can induce mRNA transcription of I-Smads. Therefore, I-Smads can tightly controll TGF-β signaling through negative feedback. What’s more, I-Smads can also inhibit Smad-mediated signal transduction, among which Smad 6 mainly inhibits BMP signal transduction, while Smad 7 inhibits TGF-β and BMP signal transduction (Figure 1) (Conidi et al., 2011; Zhang et al., 2014).
FIGURE 1. Activation of TGF-β/Smad and BMP/Smad pathways leading to Smad -mediated gene expression.
Structural Characteristics of Smad Protein
Smad proteins are made up of two conserved domains: the Mad homolog domain 1 (MH1) in the N terminus that is essential for specific DNA binding and the Mad homolog domain 2 (MH2) in the C terminus that is responsible for protein-protein interactions. And the two domains are connected by a proline-rich nonconserved intermediate linking region(L) (Liu et al., 1996; Liu, 2003). MH2 is a functional effector region and is highly conserved in all Smad proteins, the functions of which include the interaction with type I receptors, form Smad polyplexes, and bind with other transcriptional coactivators or co-inhibitors. MH1 is a functional inhibitory region of MH2, which inhibits the function of MH2 when inactivated, and responsible for binding to a specific DNA sequence when activated. Unlike MH2, MH1 is only conserved in R-Smad and Co-Smad. MH1 and MH2 connected by L region together made up the smad protein (Guzman et al., 2012). When the receptor binds with the ligand, the two molecules dissociate to form a Smad complex that migrates to the nucleus, the nuclear accumulation of which causes transcription of the target gene. At present, the function of L region remains unclear.
Smad Pathway
Although Smad pathway is present in most of the cell types and tissues, it is an additional pathway activated by TGF-β/BMP. In general, signal transduction of TGF-β and BMP ligands share many common principles. In the TGF-β pathway, when the TGF-β family ligand binds to the type II receptor, it activates the type II receptor kinase, and then phosphorylates the GS region. Before this occurs, type I receptor is catalytically inactive because the insertion of GS region into the kinase domain, dislocating the catalytic center. The phosphorylation of GS region directly leading to the phosphorylation of type I receptor, followed with R-Smads (Wrana et al., 1994; Huse et al., 2001). Phosphorylated R-Smads separate from type I receptors and form complexes with Smad 4 (Tao and Sampath, 2010). In the BMP pathway, BMPs eventually form a complex starting with the BMP type II receptor (BMPRII) kinase phosphorylating and then activating the type I receptor (BMPRI) kinase (Chan et al., 2007; Broege et al., 2013). The activated receptor complex further activates a series of downstream receptors that regulate R-Smads. During them, Smad 2 and Smad 3 are activated the TGF-β and activin receptors, whereas Smad 1, Smad 5 and Smad 8 are activated by ALK-1, ALK-2, ALK-3 and ALK-6. The phosphorylated R-Smads separated from the receptor and bind to Smad 4 to form the next complexes (Miyazono, 1999; Derynck and Zhang, 2003; Gomez-Puerto et al., 2019). These complexes formed through the TGF-β pathway and the BMP pathway are transferred to the nucleus and bind to different Smad-binding elements (SBEs), DNA transcription factors, transcriptional coactivators or co-inhibitors, and migrate into the nucleus (Conidi et al., 2013; Kopf et al., 2014). Their nuclear accumulation causes positive or negative regulation of target gene expression. For example, transcriptional co-activator with PDZ-binding motif (TAZ) is necessary for maintaining self-renewal markers in human embryonic stem cells and it is found that it is a key factor that controls the nuclear accumulation of heteromeric Smad 2/3–4 complexes. The loss of TAZ would directly lead to the failure of the complexes accumulating in the nucleus and thus inhibiting TGF-β signaling together with differentiating into a neuroectoderm lineage (Varelas et al., 2008). The N region of I-Smads is related to the specificity of other pathways and lacks MH1, which can compete with R-Smad for the type I receptor of TGF-β and BMPs, thereby surpressing the phosphorylation of R-Smad and inhibiting the Smad pathway (Bai and Cao, 2002).
Role of Smad Family in Osteoporosis Through Transforming Growth Factor-β/Bone Morphogenetic Proteins Pathway
With the trend of global population aging, the incidence of osteoporosis has also increased year by year worldwide, which seriously threatens the health of elderlies. Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures. Skeletal fragility can result from many reasons, while the only pathogenesis that can be relieved by treatment are excessive bone resorption and failure to failure to replace lost bone due to defects in bone formation (Raisz, 2005). Since OC is more active than OB, the tendency of bone resorption is always greater than that of bone formation. Therefore, regulating the balance between OB-mediated bone formation and OC-mediated bone resorption is the focus of treatment of osteoporosis (Appelman-Dijkstra and Papapoulos, 2015). Smad is directly involved in the induction of OB and OC formation and differentiation via the TGF-β/BMP pathway, which plays an integral role in the regulation of bone metabolism (Zhang et al., 2017).
Smad Protein and Osteoblast
The OB responsible for bone formation activity is derived from bone marrow derived mesenchymal stem cells (BMSCs) (Endo and Mastumoto, 2014). OB proliferation and differentiation are regulated by a variety of growth factors, including TGF-β, BMP, and Smad. Both TGF-β and BMP pathways promote bone formation, and their signal transduction is both directly mediated by Smad (Chen et al., 2012).
Smad Protein and Osteoblast in Bone Morphogenetic Proteins Pathway
BMPs were first found as proteins that induce ectopic bone formation. After discovering the ectopic induction of decalcified bone, Urist et al. believed that it may contain an inducible factor that can induce the mesenchymal cells swimming around blood vessels to transform into irreversible bone line cells which can be used in bones. The factor was then proved and named "bone morphogenetic protein" (Urist, 1965; Urist and Strates, 1971). Since then, more and more researches on BMPs made people have a wider understanding of them. As multifunctional cytokines, they are now known to play important roles in an array of processes during formation and maintenance of various organs. Liu et al. found that BMPs are effective osteophytes that induce OB differentiation and bone formation and have been shown to induce bone formation in animals (Liu et al., 2013). BMP-2 induces the differentiation of BMSCs into OB and promotes bone formation by increasing the activation of alkaline phosphatase (ALP) and the expression of genes such as osteocalcin. Among all Smad proteins, Smad 1, Smad 5, and Smad 8 are closely associated with OB differentiation (J. H. Yang et al., 2016). After binding with BMP-I type A or type I B receptors, Smad 1, Smad 5, and Smad 8 are directly activated and phosphorylated, which then form heterotrimers or heterologous dimer with one or two R-Smads and one Smad 4 to enter the nucleus and acts on the gene sequence of OB-specific transcription factors such as runx 2 and osterix to up-regulate their expression (Tao and Sampath, 2010; Yang et al., 2013; Kim et al., 2014; Kopf et al., 2014). In addition, Smad 1 or Smad 5 specifically binds to the promoter of the PEBP 2αA/AML 3/CBFA 1 gene, the lack of which can leads to incapable of both endochondral and intramembranous bone formation (Komori et al., 1997; Takazawa et al., 2000). Some researchers have found that miR-155 is down-regulated after BMP-2 stimulation, which is capable of inhibiting differentiation of OB into osteocytes. The mechanism is to inhibit gene expression by binding to the 3′-UTR end of Smad 5 mRNA (Tsuji et al., 1998). Liu et al. believed that the ubiquitination of Smad 1/5 is responsible for the age related bone formation reduction, which lead them to Pleckstrin homology domain-containing family O member 1 (PLEKHO1), a molecule that could promote the ubiquitination of Smad 1/5. After the experiment on 50 bone samples of elderly patients with fractures, they found age-related increases in PLEKHO1 mRNA levels reduce phosphorylation of Smad 1/5 (p-Smad 1/5), and inhibit OB production. In addition, osteoblast-specific Smad 1 overexpression is beneficial to bone formation during aging, and which can be counteracted after overexpressing Plekho1 within osteoblasts(Liu et al., 2017).. Recent studies have found that the ligand DLL1 of the Notch signaling pathway promotes BMP9-induced osteogenic differentiation of BMSCs both in vitro and in vivo, which may be achieved by affecting multiple aspects of the BMP9 signaling pathway. DLL1 can promote the expression of BMP type I receptor ALK2, as well as up-regulate Smad 1/5/8 phosphorylation level and SBE transcriptional activity. Moreover, a recent study suggest that bone-forming peptide (BFP)-3, derived from the immature precursor of BMP-7 can cause osteogenic differentiation of bone marrow stromal cells by regulating the Smad 1/5/8 signaling pathways (Lee et al., 2018). These findings all indicate that Smad protein is involved in the BMP signaling pathway that induce OB formation in different degrees, and the formation of OB is closely associated with phosphorylated Smad.
Smad Proteins and Osteoblasts in the Transforming Growth Factor-β Pathway
In addition to the BMP pathway, Smad also promotes OB formation through the TGF-β pathway. Transforming growth factors-β is mainly stored as a latent complex in the extracellular matrix and exists in at least three isoforms: TGF-β1, TGF-β2, and TGF-β3. TGF-β1 deficient mice display reduced bone growth and mineralization (Geiser et al., 2005). TGF-β2 and TGF-β3 double knockout mice display a lack of distal parts of the rib (Dünker and Krieglstein, 2002). During signal transduction of this pathway, TGF-β firstly binds to its type II receptor and then activates its type I receptor. Activated type I receptors result in the phosphorylation of Smad 2 or Smad 3 at a C-terminal, which then forms complexes with Smad 4 and translocated into nucleus to bind to SBE on DNA through the hairpin-like structure of the MH1 region. The R-Smad-Smad 4 complex cooperates with sequence-specific transcription factors such as ymphoid enhancer-binding factor 1/T cell factor (LEF1/TCF), ymphoid enhancer-binding factor 1/T cell factor (LEF1/TCF), core-binding factor A/acute myeloneous leukemia (CBFA/AML) and the coactivators CREB-binding protein (CBP) or p300 to activate transcription in response to TGF-β ligand (Derynck and Zhang, 2003), thus affecting osteoblast proliferation, differentiation, and type I collagen synthesis (Runyan et al., 2012; Ota et al., 2013; Li et al., 2015). Researches suggest that OB and OC can communicate with each other through direct cell-cell contact, cytokines and extracellular matrix interaction (Chen et al., 2018). The connection between them and with outside is mediated by hemi-channels and gap junctions (GJ). And the communication between cells mediated by GJ is called gap junctional intercellular communication (GJIC), which plays an important role in the skeletal network, including participation in mechanical mechanotransduction, intracortical bone resorption and bone remodeling, regulating bone cell survival, etc (Plotkin et al., 2015; Xu et al., 2015). While the main component of GJ is connexin, during which connexin 43 (Cx43) is most highly expressed in bone, meaning it is closely related to the communication between OB and OC and the whole skeletal network. For exmple, Liu et al. found that the expression of Cx43 is related to the Smad-dependent TGF-β signaling pathway (Liu et al., 2018). The complex formed by Smad 2 or Smad 3 combined with Smad 4 can upregulate the expression of the target gene Cx43, thereby participating in the activities of bone cells, which indirectly verified the effect of Smad protein on bone cells in the TGF-β pathway again. Some researchers reported that puerarin promotes bone formation by stimulating the expression of Smad 2/3 mRNA and stimulating the secretion and synthesis of TGF-β1 (Okada et al., 2013). In addition, TGF-β can also induce self-expression of OB and induce BMP-2 expression in OB, enhancing its osteogenic capacity.
Smad Protein and Osteoclasts
OCs responsible for bone resorption activity originate from hematopoietic stem cells. The formation of OC depends on the synergy of nuclear factor κB receptor activating factor ligand (RANKL) and colony stimulating factor 1 (CSF-1), both of which are secreted by OBs(Boyce, 2013). CSF-1 binds to its receptor activation signal pathway on the surface of immature OC and is essential for the proliferation and survival of OC precursors. RANKL promotes the formation, activation and survival of mature OC by binding to RANK on the surface of osteoclast precursor cells through both membrane-bound and soluble forms. They are essential for osteoclast formation and function because the mice lacking of them are found fail to form osteoclasts under homeostatic conditions, contributing to severe diseases such as osteopetrosis accompanied by a defect in tooth eruption (Dougall et al., 1999).
Smad Protein and Osteoclasts in Transforming Growth Factor-β Pathway
Up to now, it is known that TGF-β is closely associated with the production and differentiation of OC. The differentiation of osteoclast is mainly mediated by RANKL/RANK pathway as RANKL would bind to macrophage colony stimulating factor to induce OC formation. While the existence of osteoprotegerin (OPG), a soluble decoy receptor can block osteoclast precursor differentiation by binding RANKL. The three of them maintain a certain balance until diseases such as osteoporosis occurs and inhibiting the RANKL/RANK pathway to inhibit osteoclast has been proven to be effective, which can also be reversely verified for the OPG knockout mice have osteoporosis (Mizuno et al., 1998; Nakashima and Takayanagi, 2011; Bae et al., 2017). In this process, on one hand, TGF-β was found to be able to directly act on bone marrow macrophages (BMMs) to promote the formation of OCs (Sriarj et al., 2015). On the other hand, it can also indirectly regulate the balance of RANKL with OPG to affect the differentiation of OC, which is complicated because TGF-β has not only been shown to stimulate OPG production in bone marrow stromal and osteoblastic cells (Takai et al., 1998), but also be thought to promote OC differentiation with the stimulation of RANKL (Yan et al., 2001; Fox and Lovibond, 2005; Sriarj et al., 2015). There are two main explanations for this contradictory effect in academia. One believes that it depends on the different model systems used in vitro experiments. The others balme on the different of the stage that TGF-β play its role as well as its concentration (Karst et al., 2004). In addition to that, the expression of downstream genes of the RANKL/RANK pathway is also inseparable from TGF and its activated Smad protein. Molecules such as TNF receptor-associated factor 6 (TRAF6), NF-κB, MAPK, and activator protein 1 (AP-1) have been identified as downstream mediators of RANK/RANKL signaling, and all of which are thought to influence osteoclasts through their effects on a common transcription factor, nuclear factor of activated T cell (NFATc1) (Nakashima and Takayanagi, 2011; Bae et al., 2017). NFATc1 has already been proved to be a key factor regulating OC differentiation because NFATc1-deficient embryonic stem cells cannot differentiate into osteoclasts and targeted disruption of Nfatc1 in hematopoietic cells in mice increases bone mass, with a marked decrease in osteoclasts (Takayanagi et al., 2002). While TGF-β can enhance RANKL-mediated translocation of complexes formed by Smad 2 or Smad 3 with Smad 4 into the nucleus and binds to the NFATc1 target gene, driving expression of NFATc1 (Fennen et al., 2016). In this process, binding of TRAF6 to the MH2 domain of Smad 3 is also important for the RANKL/RANK signal transduction (Fennen et al., 2016). Yasui et al. found that when the Smad pathway was blocked, induction of OC formation by RANKL was inhibited, but the activated mutant Smad 2 or Smad 3 could reverse this effect. Immunoprecipitation analysis revealed that Smad 2/3 directly forms a complex with TRAF6-TAB1-TAK1, which can stimulate RANKL and promote OC differentiation. Further analysis revealed that the MH2 region of Smad 3 was essential for the TRAF6-TAB1-TAK1 complex formation. TGF-β stimulates the activation of Smad 2 or Smad 3, and Smad 2 or Smad 3 binds directly to TRAF6-TAB1-TAK1 to form a complex that can promote RANKL-induced OC formation (Figure 2) (Yasui et al., 2011).
FIGURE 2. TGF-β/Smad signaling during osteoclast differentiation. The activation of Smad 2/3 by TGF-β, and Smad 2/3 binds directly to TRAF6-TAB1-TAK1 to form a complex that can promote RANKL-induced osteoclast differentiation.
Smad Proteins and Osteoclasts in the Bone Morphogenetic Proteins Pathway
Among BMPs, BMP-2 is closely associated with the formation of OC, also stimulates the bone resorption activity of OC. BMP-2 mainly induces the expression of CSF-1 to promote OC formation (Sun et al., 2014). It also mediates Smad of the BMP pathway to synergize with the CREB-binding protein to increase the expression of CSF-1, and the up-regulation of CSF-1 further promotes OC production (Mandal et al., 2009). In RANKL/RANK pathway, RANKL and BMP-2 can increase their expression under the action of interleukin-1α to promote OC formation, improve the survival rate of OC, and promote the differentiation of OC(Liu et al., 2005). Nevertheless, BMP-2 alone cannot improve the survival rate of OC. Yoshikawa et al. (Yoshikawa et al., 2015)found that BMP-2-induced RANKL mRNA expression was inhibited in the primary Smad 1 knockout OB, resulting in decreased OC formation. In addition to Smad 2 and Smad 3 responsible for mediating TGF-β signaling pathways and Smad 1 and Smad 5 responsible for mediating BMP pathways, Smad 4, as a Co-Smad binds to R-Smads that are phosphorylated by TGF-β/BMP stimulation, also paticipate in the formation of OC as a matter of course. Amy et al. found that after knockout of Smad 1, 4 and 5, respectively, bone resorption activity of OC decreased, and the expression of OC differentiation markers was also decreased, indicating that expression of Smad 1, 4 and 5 is necessary for the differentiation of OC(Tasca et al., 2015). In addition, Li et al.used mice with exon 1 of the Smad 7 gene knocked out to mimic the functional loss of Smad 7. Compared with normal mice, there was no significant difference in the morphology and length of the metaphysis of the left femur, but bone mass and trabecular bone were lower than those of the control group. More OCs were found under the microscope when compared with the control group. This shows that partial loss of Smad 7 function inhibits bone formation and promotes bone resorption, suggesting the promotion of Smad 7 to osteoclast formation (Li et al., 2014).
Therapeutic Potential of Smad Signaling Regulators for Treatment of Osteoporosis
Smad has major effects on the induction of OB and OC production and differentiation through TGF-β/BMP pathway under various circumstances, which plays a significant role in the regulation of bone metabolism. Although precise regulatory mechanisms are not well understood, inhibitors and activators targeting the Smad signaling pathway can certainly produce specific effects on the treatment of osteoporosis. Table 1 lists a range of signaling pathway inhibitors for popular targets. For example, since the Smad pathway activated by TGF-β pathway is initiated by phosphorylation of type I receptors, small molecule inhibitors targeting TGFI type kinase domain can inhibit the activation of the Smad pathway (Wang et al., 2020c). Scios (Johnson & Johnson) developed a small molecule, orally active TGFI type kinase inhibitor called SD-208, which can block the TGF-β-induced phosphorylation of the Smad 2/Smad 3 in a dose-dependent manner (Wang et al., 2020b). Experiments by Mohammad et al. in mice proved this point and the results showed that SD-208, an inhibitor that blocks the TGF-Smad pathway can prevent Experiments by Mohammad et al. in mice proved this and the results showed that SD-208, an inhibitor that blocks the TGF-β-Smad signaling pathway can prevent the development and progression of melanoma bone metastases (Mohammad et al., 2011). Wei et al. used the SBE-bla assay as a novel first-tier screen to determine whether a chemical has the potential to inhibit TGFβ1-induced Smad 2/3/4 signaling, which provides us train of thought that more chemicals can therefore be discovered and put into test in bone remodeling (Wei et al., 2019). In addition, there are some known TGF-β/Smad inhibitors having been put into clinical practice such as pirfenidone and haloperidol hydrochloride, which having shown to be effective. While in BMP-Smad pathway, blocking Smad 1/5/8 phosphorylation with dorsomorphin is proved to prevent terminal differentiation and mineralization of cartilage tissue while sustaining further cartilagematrix production (Hellingman et al., 2011). Similarly, it reminds us that compounds or drugs which is able to activate Smad signaling pathway through TGF-β or BMP pathway have a adjusting function to osteoporosis (Wang et al., 2020d). Of course, the direction ultimately depends on the specific cells they regulate. Therefore, we also summarize a list of activators of Smad pathway (Table 2), hoping that experiments on function of these compounds in osteoporosis can be carried out. However, since the TGF/BMP pathway is ubiquitous in the human body, the regulation of one place is likely to involve another. For example, when considering promoting osteoblast formation through the TGF-β pathway, TGF-β activation in bone tendon insertion would induce enthesopathy-like disease should also be considered (Wang et al., 2018). Related regulatory mechanisms should be studied more precisely, and the location and concentration of the drug should also be limited to avoid side effects.
TABLE 1. Inhibitors of Smad signaling pathway.
TABLE 2. Activators of smad signaling pathway.
Prospect of Smad in Osteoporosis Research
In conclusion, pathogenesis of osteoporosis is mainly an imbalance of bone homeostasis between OB-mediated bone formation and OC-mediated bone resorption (Yang and Duan, 2016). Smad directly participates in the induction of OB and OC production and differentiation through TGF-β/BMP pathway under different circumstances, which plays a significant role in regulating bone metabolism (Liu et al., 2014). However, the current research on Smad is still at early stage. The researches on bone formation and bone resorption are mainly limited to animal studies, with few direct study on osteoporosis patients. The precise regulation mechanism of Smad is also not fully understood. Smads is involved in regulation of TGF-β/BMP pathway, and contribute to the formation of both OB and OC. It has not been fully understood that which factors can induce Smad to promote OB formation, and which factors can induce Smad to promote OC formation. Further relevant studies are necessary to explore the specific mechanisms and influencing factors of Smad’s role in bone formation and bone resorption. How to promote the formation of OB while avoiding the formation of OC will be a hot topic for future research on drugs for the prevention and treatment of osteoporosis.
Author Contributions
F-LY and R-SX designed whole the study; M-LZ, Z-HC, Z-DY, and J-JW drafted the manuscript; M-LZ, XL, Z-LS, S-YL, YJ, and K-WZ critically reviewed the studies; Z-HC and Y-YT performed the systematic review; F-LY, R-SX, and YF reviewed and revised the manuscript.
Funding
Funding for this study was provided by the Natural Science Foundation of China (81770876), Natural Science Foundation of Jiangsu Province (Grant BK20191141).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Ali, I. H. A., and Brazil, D. P. (2014). Bone Morphogenetic Proteins and Their Antagonists: Current and Emerging Clinical Uses. Br. J. Pharmacol. 171, 3620–3632. doi:10.1111/bph.12724
Bae, S., Lee, M. J., Mun, S. H., Giannopoulou, E. G., Yong-Gonzalez, V., Cross, J. R., et al. (2017). MYC-dependent Oxidative Metabolism Regulates Osteoclastogenesis via Nuclear Receptor ERRα. J. Clin. Invest. 127, 2555–2568. doi:10.1172/JCI89935
Bai, S., and Cao, X. (2002). A Nuclear Antagonistic Mechanism of Inhibitory Smads in Transforming Growth Factor-β Signaling. J. Biol. Chem. 277 (6), 4176–4182. doi:10.1074/jbc.m105105200
Boyce, B. F. (2013). Advances in the Regulation of Osteoclasts and Osteoclast Functions. J. Dent Res. 92, 860–867. doi:10.1177/0022034513500306
Broege, A., Pham, L., Jensen, E. D., Emery, A., Huang, T.-H., Stemig, M., et al. (2013). Bone Morphogenetic Proteins Signal via SMAD and Mitogen-Activated Protein (MAP) Kinase Pathways at Distinct Times during Osteoclastogenesis. J. Biol. Chem. 288, 37230–37240. doi:10.1074/jbc.M113.496950
Chaikuad, A., Alfano, I., Kerr, G., Sanvitale, C. E., Boergermann, J. H., Triffitt, J. T., et al. (2012). Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva*. J. Biol. Chem. 287, 36990–36998. doi:10.1074/jbc.M112.365932
Chan, M. C., Nguyen, P. H., Davis, B. N., Ohoka, N., Hayashi, H., Du, K., et al. (2007). A Novel Regulatory Mechanism of the Bone Morphogenetic Protein (BMP) Signaling Pathway Involving the Carboxyl-Terminal Tail Domain of BMP Type II Receptor. Mcb 27, 5776–5789. doi:10.1128/MCB.00218-07
Chen, G., Deng, C., and Li, Y.-P. (2012). TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation. Int. J. Biol. Sci. 8 (2), 272–288. doi:10.7150/ijbs.2929
Chen, W., Fu, X., and Sheng, Z. (2002). Review of Current Progress in the Structure and Function of Smad Proteins. Chin. Med. J. 115 (3), 446–450.
Chen, X., Wang, Z., Duan, N., Zhu, G., Schwarz, E. M., and Xie, C. (2018). Osteoblast-osteoclast Interactions. Connect. Tissue Res. 59, 99–107. doi:10.1080/03008207.2017.1290085
Conidi, A., Cazzola, S., Beets, K., Coddens, K., Collart, C., Cornelis, F., et al. (2011). Few Smad Proteins and Many Smad-Interacting Proteins Yield Multiple Functions and Action Modes in TGF-β/BMP Signaling In Vivo. Cytokine Growth Factor. Rev. 22 (5-6), 287–300. doi:10.1016/j.cytogfr.2011.11.006
Conidi, A., van den Berghe, V., and Huylebroeck, D. (2013). Aptamers and Their Potential to Selectively Target Aspects of EGF, Wnt/β-Catenin and TGFβ-Smad Family Signaling. Ijms 14 (4), 6690–6719. doi:10.3390/ijms14046690
De Boeck, M., and ten Dijke, P. (2012). Key Role for Ubiquitin Protein Modification in TGFβ Signal Transduction. Upsala J. Med. Sci. 117, 153–165. doi:10.3109/03009734.2012.654858
Derynck, R., Gelbart, W. M., Harland, R. M., Heldin, C.-H., Kern, S. E., Massagué, J., et al. (1996). Nomenclature: Vertebrate Mediators of TGFβ Family Signals. Cell 87 (2), 173. doi:10.1016/s0092-8674(00)81335-5
Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent Pathways in TGF-β Family Signalling. Nature 425, 577–584. doi:10.1038/nature02006
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., et al. (1999). RANK Is Essential for Osteoclast and Lymph Node Development. Genes Dev. 13, 2412–2424. doi:10.1101/gad.13.18.2412
Dünker, N., and Krieglstein, K. (2002). Tgfß2 -/- Tgfß3 -/- Double Knockout Mice Display Severe Midline Fusion Defects and Early Embryonic Lethality. Anat. Embryol. 206, 73–83. doi:10.1007/s00429-002-0273-6
Endo, I., and Mastumoto, T. (2014). [Bone and Stem Cells. Regulatory Mechanism of Mesenchymal Stem Cell Differentiation to Osteoblasts]. Clin. Calcium 24 (4), 555–564.
Feng, X.-H., and Derynck, R. (2005). Specificity and Versatility in Tgf-Β Signaling through Smads. Annu. Rev. Cel Dev. Biol. 21, 659–693. doi:10.1146/annurev.cellbio.21.022404.142018
Fennen, M., Pap, T., and Dankbar, B. (2016). Smad-dependent Mechanisms of Inflammatory Bone Destruction. Arthritis Res. Ther. 18, 279. doi:10.1186/s13075-016-1187-7
Fox, S. W., and Lovibond, A. C. (2005). Current Insights into the Role of Transforming Growth Factor-β in Bone Resorption. Mol. Cell Endocrinol. 243, 19–26. doi:10.1016/j.mce.2005.09.008
Geiser, A. G., Hummel, C. W., Draper, M. W., Henck, J. W., Cohen, I. R., Rudmann, D. G., et al. (2005). A New Selective Estrogen Receptor Modulator with Potent Uterine Antagonist Activity, Agonist Activity in Bone, and Minimal Ovarian Stimulation. Endocrinology 146, 4524–4535. doi:10.1210/en.2005-0024
Gomez-Puerto, M. C., Iyengar, P. V., García de Vinuesa, A., Ten Dijke, P., and Sanchez-Duffhues, G. (2019). Bone Morphogenetic Protein Receptor Signal Transduction in Human Disease. J. Pathol. 247, 9–20. doi:10.1002/path.5170
Guzman, A., Femiak, M. Z., Boergermann, J. H., Paschkowsky, S., Kreuzaler, P. A., Fratzl, P., et al. (2012). SMAD versus Non-SMAD Signaling Is Determined by Lateral Mobility of Bone Morphogenetic Protein (BMP) Receptors*. J. Biol. Chem. 287 (47), 39492–39504. doi:10.1074/jbc.m112.387639
Hellingman, C. A., Davidson, E. N. B., Koevoet, W., Vitters, E. L., van den Berg, W. B., van Osch, G. J. V. M., et al. (2011). Smad Signaling Determines Chondrogenic Differentiation of Bone-Marrow-Derived Mesenchymal Stem Cells: Inhibition of Smad1/5/8P Prevents Terminal Differentiation and Calcification. Tissue Eng. A 17, 1157–1167. doi:10.1089/ten.TEA.2010.0043
Hu, B., Yu, B., Tang, D., Li, S., and Wu, Y. (2016). Daidzein Promotes Osteoblast Proliferation and Differentiation in OCT1 Cells through Stimulating the Activation of BMP-2/Smads Pathway. Genet. Mol. Res. 15. doi:10.4238/gmr.15028792
Huse, M., Muir, T. W., Xu, L., Chen, Y.-G., Kuriyan, J., and Massagué, J. (2001). The TGFβ Receptor Activation Process. Mol. Cel 8, 671–682. doi:10.1016/s1097-2765(01)00332-x
Jadai, R., Venna, N., Ajumeera, R., and Challa, S. (2019). Isoflavones Rich Cowpea and Vitamin D Induces the Proliferation and Differentiation of Human Osteoblasts via BMP‐2/Smad Pathway Activation: Mechanistic Approach. IUBMB Life 71, 1794–1805. doi:10.1002/iub.2127
Kajita, T., Ariyoshi, W., Okinaga, T., Mitsugi, S., Tominaga, K., and Nishihara, T. (2018). Mechanisms Involved in Enhancement of Osteoclast Formation by activin‐A. J. Cel. Biochem. 119, 6974–6985. doi:10.1002/jcb.26906
Karst, M., Gorny, G., Galvin, R. J. S., and Oursler, M. J. (2004). Roles of Stromal Cell RANKL, OPG, and M‐CSF Expression in Biphasic TGF‐β Regulation of Osteoclast Differentiation. J. Cel. Physiol. 200, 99–106. doi:10.1002/jcp.20036
Katagiri, T., and Tsukamoto, S. (2013). The Unique Activity of Bone Morphogenetic Proteins in Bone: a Critical Role of the Smad Signaling Pathway. Biol. Chem. 394, 703–714. doi:10.1515/hsz-2012-0310
Kenkre, J., and Bassett, J. (2018). The Bone Remodelling Cycle. Ann. Clin. Biochem. 55 (3), 308–327. doi:10.1177/0004563218759371
Kim, H.-Y., Park, S.-Y., and Choung, S.-Y. (2018). Enhancing Effects of Myricetin on the Osteogenic Differentiation of Human Periodontal Ligament Stem Cells via BMP-2/Smad and ERK/JNK/p38 Mitogen-Activated Protein Kinase Signaling Pathway. Eur. J. Pharmacol. 834, 84–91. doi:10.1016/j.ejphar.2018.07.012
Kim, M.-B., Song, Y., and Hwang, J.-K. (2014). Kirenol Stimulates Osteoblast Differentiation through Activation of the BMP and Wnt/β-Catenin Signaling Pathways in MC3T3-E1 Cells. Fitoterapia 98, 59–65. doi:10.1016/j.fitote.2014.07.013
Kim, M. S., and Jin, W. (2020). TrkB-Induced Inhibition of R-SMAD/SMAD4 Activation Is Essential for TGF-β-Mediated Tumor Suppressor Activity. Cancers 12, 1048. doi:10.3390/cancers12041048
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation Owing to Maturational Arrest of Osteoblasts. Cell 89, 755–764. doi:10.1016/s0092-8674(00)80258-5
Kopf, J., Paarmann, P., Hiepen, C., Horbelt, D., and Knaus, P. (2014). BMP Growth Factor Signaling in a Biomechanical Context. Biofactors 40 (2), 171–187. doi:10.1002/biof.1137
Kunzmann, S., Ottensmeier, B., Speer, C. P., and Fehrholz, M. (2018). Effect of progesterone on Smad signaling and TGF-β/Smad-regulated genes in lung epithelial cells. PLoS One 13 (7), e0200661. doi:10.1371/journal.pone.0200661
Lee, J. S., Kim, M. E., Seon, J. K., Kang, J. Y., Yoon, T. R., Park, Y.-D., et al. (2018). Bone-forming Peptide-3 Induces Osteogenic Differentiation of Bone Marrow Stromal Cells via Regulation of the ERK1/2 and Smad1/5/8 Pathways. Stem Cel Res. 26, 28–35. doi:10.1016/j.scr.2017.11.016
Lee, K.-W., Yook, J.-Y., Son, M.-Y., Kim, M.-J., Koo, D.-B., Han, Y.-M., et al. (2010). Rapamycin Promotes the Osteoblastic Differentiation of Human Embryonic Stem Cells by Blocking the mTOR Pathway and Stimulating the BMP/Smad Pathway. Stem Cell Dev. 19, 557–568. doi:10.1089/scd.2009.0147
Lemaire, V., Tobin, F. L., Greller, L. D., Cho, C. R., and Suva, L. J. (2004). Modeling the Interactions between Osteoblast and Osteoclast Activities in Bone Remodeling. J. Theor. Biol. 229 (3), 293–309. doi:10.1016/j.jtbi.2004.03.023
Li, H., Nie, B. e., Du, Z., Zhang, S., Long, T., and Yue, B. (2018). Bacitracin Promotes Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells by Stimulating the Bone Morphogenetic protein-2/Smad axis. Biomed. Pharmacother. 103, 588–597. doi:10.1016/j.biopha.2018.04.084
Li, J., Qu, X., Yao, J., Caruana, G., Ricardo, S. D., Yamamoto, Y., et al. (2010). Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy. Diabetes 59, 2612–2624. doi:10.2337/db09-1631
Li, J., Tang, X., and Chen, X. (2011). Comparative Effects of TGF-β2/Smad2 and TGF-β2/Smad3 Signaling Pathways on Proliferation, Migration, and Extracellular Matrix Production in a Human Lens Cell Line. Exp. Eye Res. 92, 173–179. doi:10.1016/j.exer.2011.01.009
Li, N., Lee, W. Y.-W., Lin, S.-E., Ni, M., Zhang, T., Huang, X.-R., et al. (2014). Partial Loss of Smad7 Function Impairs Bone Remodeling, Osteogenesis and Enhances Osteoclastogenesis in Mice. Bone 67, 46–55. doi:10.1016/j.bone.2014.06.033
Li, X. L., Liu, Y. B., Ma, E. G., Shen, W. X., Li, H., and Zhang, Y. N. (2015). Synergistic Effect of BMP9 and TGF-β in the Proliferation and Differentiation of Osteoblasts. Genet. Mol. Res. 14, 7605–7615. doi:10.4238/2015.july.13.4
Liu, D.-D., Ge, K., Jin, Y., Sun, J., Wang, S.-X., Yang, M.-S., et al. (2014). Terbium Promotes Adhesion and Osteogenic Differentiation of Mesenchymal Stem Cells via Activation of the Smad-dependent TGF-β/BMP Signaling Pathway. J. Biol. Inorg. Chem. 19, 879–891. doi:10.1007/s00775-014-1119-4
Liu, D.-D., Zhang, J.-C., Zhang, Q., Wang, S.-X., and Yang, M.-S. (2013). TGF-β/BMP Signaling Pathway Is Involved in Cerium-Promoted Osteogenic Differentiation of Mesenchymal Stem Cells. J. Cel. Biochem. 114 (5), 1105–1114. doi:10.1002/jcb.24451
Liu, D., Yao, S., Pan, F., and Wise, G. E. (2005). Chronology and Regulation of Gene Expression of RANKL in the Rat Dental Follicle. Eur. J. Oral Sci. 113, 404–409. doi:10.1111/j.1600-0722.2005.00245.x
Liu, F., Hata, A., Baker, J. C., Doody, J., Cárcamo, J., Harland, R. M., et al. (1996). A Human Mad Protein Acting as a BMP-Regulated Transcriptional Activator. Nature 381, 620–623. doi:10.1038/381620a0
Liu, F. (2003). Receptor Regulated SMADS in TGF Beta Signaling. Front. Biosci. 8, s1280–1303. doi:10.2741/1149
Liu, J., Liang, C., Guo, B., Wu, X., Li, D., Zhang, Z., et al. (2017). Increased PLEKHO1 within Osteoblasts Suppresses Smad-dependent BMP Signaling to Inhibit Bone Formation during Aging. Aging Cell 16, 360–376. doi:10.1111/acel.12566
Liu, W., Cui, Y., Sun, J., Cai, L., Xie, J., and Zhou, X. (2018). Transforming Growth Factor-Β1 Up-Regulates Connexin43 Expression in Osteocytes via Canonical Smad-dependent Signaling Pathway. Biosci. Rep. 38. doi:10.1042/bsr20181678
Luo, K. (2017). Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways. Cold Spring Harb Perspect. Biol. 9, a022137. doi:10.1101/cshperspect.a022137
Ma, T.-T., and Meng, X.-M. (2019). TGF-β/Smad and Renal Fibrosis. Adv. Exp. Med. Biol. 1165, 347–364. doi:10.1007/978-981-13-8871-2_16
Majidinia, M., Sadeghpour, A., and Yousefi, B. (2018). The Roles of Signaling Pathways in Bone Repair and Regeneration. J. Cel Physiol 233 (4), 2937–2948. doi:10.1002/jcp.26042
Mandal, C. C., Ghosh Choudhury, G., and Ghosh-Choudhury, N. (2009). Phosphatidylinositol 3 kinase/Akt Signal Relay Cooperates with Smad in Bone Morphogenetic Protein-2-Induced Colony Stimulating Factor-1 (CSF-1) Expression and Osteoclast Differentiation. Endocrinol. 150, 4989–4998. doi:10.1210/en.2009-0026
McGowan, J. A. (1993). Osteoporosis: Assessment of Bone Loss and Remodeling. Aging Clin. Exp. Res. 5 (2), 81–93. doi:10.1007/bf03324132
Miyazono, K. (1999). Signal Transduction by Bone Morphogenetic Protein Receptors: Functional Roles of Smad Proteins. Bone 25, 91–93. doi:10.1016/s8756-3282(99)00113-1
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., et al. (1998). Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/osteoprotegerin. Biochem. Biophysical Res. Commun. 247, 610–615. doi:10.1006/bbrc.1998.8697
Mohammad, K. S., Javelaud, D., Fournier, P. G. J., Niewolna, M., McKenna, C. R., Peng, X. H., et al. (2011). TGF-β-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Res. 71, 175–184. doi:10.1158/0008-5472.CAN-10-2651
Nakagawa, T., Li, J. H., Garcia, G., Mu, W., Piek, E., Böttinger, E. P., et al. (2004). TGF-β Induces Proangiogenic and Antiangiogenic Factorsvia Parallel but Distinct Smad Pathways1. Kidney Int. 66, 605–613. doi:10.1111/j.1523-1755.2004.00780.x
Nakashima, T., and Takayanagi, H. (2011). New Regulation Mechanisms of Osteoclast Differentiation. Ann. N. Y. Acad. Sci. 1240, E13–E18. doi:10.1111/j.1749-6632.2011.06373.x
Okada, M., Kim, J. H., Hutton, W. C., and Yoon, S. T. (2013). Upregulation of Intervertebral Disc-Cell Matrix Synthesis by Pulsed Electromagnetic Field Is Mediated by Bone Morphogenetic Proteins. J. Spinal Disord. Tech. 26, 167–173. doi:10.1097/BSD.0b013e31823d36cf
Osman, B., Doller, A., Akool, E.-S., Holdener, M., Hintermann, E., Pfeilschifter, J., et al. (2009). Rapamycin Induces the TGFβ1/Smad Signaling Cascade in Renal Mesangial Cells Upstream of mTOR. Cell Signal. 21, 1806–1817. doi:10.1016/j.cellsig.2009.07.016
Ota, K., Quint, P., Ruan, M., Pederson, L., Westendorf, J. J., Khosla, S., et al. (2013). TGF-β Induces Wnt10b in Osteoclasts from Female Mice to Enhance Coupling to Osteoblasts. Endocrinology 154, 3745–3752. doi:10.1210/en.2013-1272
Plotkin, L. I., Speacht, T. L., and Donahue, H. J. (2015). Cx43 and Mechanotransduction in Bone. Curr. Osteoporos. Rep. 13, 67–72. doi:10.1007/s11914-015-0255-2
Qi, G., Lu, G., Yu, J., Zhao, Y., Wang, C., Zhang, H., et al. (2019). Up-regulation of TIF1γ by Valproic Acid Inhibits the Epithelial Mesenchymal Transition in Prostate Carcinoma through TGF-β/Smad Signaling Pathway. Eur. J. Pharmacol. 860, 172551. doi:10.1016/j.ejphar.2019.172551
Raftery, L. A., and Sutherland, D. J. (1999). TGF-β Family Signal Transduction in Drosophila Development: From Mad to Smads. Dev. Biol. 210, 251–268. doi:10.1006/dbio.1999.9282
Raisz, L. G. (2005). Pathogenesis of Osteoporosis: Concepts, Conflicts, and Prospects. J. Clin. Invest. 115, 3318–3325. doi:10.1172/JCI27071
Runyan, C. E., Liu, Z., and Schnaper, H. W. (2012). Phosphatidylinositol 3-Kinase and Rab5 GTPase Inversely Regulate the Smad Anchor for Receptor Activation (SARA) Protein Independently of Transforming Growth Factor-Β1. J. Biol. Chem. 287, 35815–35824. doi:10.1074/jbc.m112.380493
Sakata, T., and Chen, J. K. (2011). Chemical 'Jekyll and Hyde's: Small-Molecule Inhibitors of Developmental Signaling Pathways. Chem. Soc. Rev. 40, 4318–4331. doi:10.1039/c1cs15019g
Sánchez-Duffhues, G., Hiepen, C., Knaus, P., and ten Dijke, P. (2015). Bone Morphogenetic Protein Signaling in Bone Homeostasis. Bone 80, 43–59. doi:10.1016/j.bone.2015.05.025
Sekelsky, J. J., Newfeld, S. J., Raftery, L. A., Chartoff, E. H., and Gelbart, W. M. (1995). Genetic Characterization and Cloning of Mothers against Dpp, a Gene Required for Decapentaplegic Function in Drosophila melanogaster. Genetics 139, 1347–1358. doi:10.1093/genetics/139.3.1347
Shan, Y., Yang, F., Tang, Z., Bi, C., Sun, S., Zhang, Y., et al. (2018). Dexmedetomidine Ameliorates the Neurotoxicity of Sevoflurane on the Immature Brain through the BMP/SMAD Signaling Pathway. Front. Neurosci. 12, 964. doi:10.3389/fnins.2018.00964
Silvestri, L., Nai, A., Dulja, A., and Pagani, A. (2019). Hepcidin and the BMP-SMAD Pathway: An Unexpected Liaison. Vitam. Horm. 110, 71–99. doi:10.1016/bs.vh.2019.01.004
Song, H. W., Kumar, B. K., Kim, S. H., Jeon, Y. H., Lee, Y. A., Lee, W. T., et al. (2011). Agmatine Enhances Neurogenesis by Increasing ERK1/2 Expression, and Suppresses Astrogenesis by Decreasing BMP 2,4 and SMAD 1,5,8 Expression in Subventricular Zone Neural Stem Cells. Life Sci. 89, 439–449. doi:10.1016/j.lfs.2011.07.003
Sriarj, W., Aoki, K., Ohya, K., Takahashi, M., Takagi, Y., and Shimokawa, H. (2015). TGF-β in Dentin Matrix Extract Induces Osteoclastogenesis In Vitro. Odontol. 103, 9–18. doi:10.1007/s10266-013-0140-3
Sun, S. X., Guo, H. H., Zhang, J., Yu, B., Sun, K. N., and Jin, Q. H. (2014). BMP-2 and Titanium Particles Synergistically Activate Osteoclast Formation. Braz. J. Med. Biol. Res. 47, 461–469. doi:10.1590/1414-431x20132966
Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., et al. (1998). Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells. J. Biol. Chem. 273, 27091–27096. doi:10.1074/jbc.273.42.27091
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., et al. (2002). Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts. Dev. Cel 3, 889–901. doi:10.1016/s1534-5807(02)00369-6
Takazawa, Y., Tsuji, K., Nifuji, A., Kurosawa, H., Ito, Y., and Noda, M. (2000). An Osteogenesis-Related Transcription Factor, Core-Binding Factor A1, Is Constitutively Expressed in the Chondrocytic Cell Line TC6, and its Expression Is Upregulated by Bone Morphogenetic Protein-2. J. Endocrinol. 165, 579–586. doi:10.1677/joe.0.1650579
Tao, S., and Sampath, K. (2010). Alternative Splicing of SMADs in Differentiation and Tissue Homeostasis. Dev. Growth Differ. 52 (4), 335–342. doi:10.1111/j.1440-169x.2009.01163.x
Tasca, A., Stemig, M., Broege, A., Huang, B., Davydova, J., Zwijsen, A., et al. (2015). Smad1/5 and Smad4 Expression Are Important for Osteoclast Differentiation. J. Cel. Biochem. 116, 1350–1360. doi:10.1002/jcb.25092
Tsuji, K., Ito, Y., and Noda, M. (1998). Expression of the PEBP2αA/AML3/CBFA1 Gene Is Regulated by BMP4/7 Heterodimer and its Overexpression Suppresses Type I Collagen and Osteocalcin Gene Expression in Osteoblastic and Nonosteoblastic Mesenchymal Cells. Bone 22, 87–92. doi:10.1016/s8756-3282(97)00267-6
Urist, M. R. (1965). Bone: Formation by Autoinduction. Science 150, 893–899. doi:10.1126/science.150.3698.893
Urist, M. R., and Strates, B. S. (1971). Bone Morphogenetic Protein. J. Dent. Res. 50, 1392–1406. doi:10.1177/00220345710500060601
Urrutia, H., Aleman, A., and Eivers, E. (2016). Drosophila Dullard Functions as a Mad Phosphatase to Terminate BMP Signaling. Sci. Rep. 6, 32269. doi:10.1038/srep32269
Varelas, X., Sakuma, R., Samavarchi-Tehrani, P., Peerani, R., Rao, B. M., Dembowy, J., et al. (2008). TAZ Controls Smad Nucleocytoplasmic Shuttling and Regulates Human Embryonic Stem-Cell Self-Renewal. Nat. Cel Biol. 10, 837–848. doi:10.1038/ncb1748
Wang, G., Li, C., Wang, Y., and Chen, G. (2013). Cooperative Assembly of Co-smad4 MH1 with R-Smad1/3 MH1 on DNA: a Molecular Dynamics Simulation Study. PLoS One 8, e53841. doi:10.1371/journal.pone.0053841
Wang, H., Chen, F., Li, J., Wang, Y., Jiang, C., Wang, Y., et al. (2020a). Vaspin Antagonizes High Fat-Induced Bone Loss in Rats and Promotes Osteoblastic Differentiation in Primary Rat Osteoblasts through Smad-Runx2 Signaling Pathway. Nutr. Metab. (Lond) 17, 9. doi:10.1186/s12986-020-0429-5
Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., et al. (2020b). Development of Small Molecule Inhibitors Targeting TGF-β Ligand and Receptor: Structures, Mechanism, Preclinical Studies and Clinical Usage. Eur. J. Med. Chem. 191, 112154. doi:10.1016/j.ejmech.2020.112154
Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., et al. (2020c). Development of Small Molecule Inhibitors Targeting TGF-β Ligand and Receptor: Structures, Mechanism, Preclinical Studies and Clinical Usage. Eur. J. Med. Chem. 191, 112154. doi:10.1016/j.ejmech.2020.112154
Wang, W., Rigueur, D., and Lyons, K. M. (2020d). TGFβ as a Gatekeeper of BMP Action in the Developing Growth Plate. Bone 137, 115439. doi:10.1016/j.bone.2020.115439
Wang, X., Xie, L., Crane, J., Zhen, G., Li, F., Yang, P., et al. (2018). Aberrant TGF-β Activation in Bone Tendon Insertion Induces Enthesopathy-like Disease. J. Clin. Invest. 128, 846–860. doi:10.1172/JCI96186
Wei, Z., Sakamuru, S., Zhang, L., Zhao, J., Huang, R., Kleinstreuer, N. C., et al. (2019). Identification and Profiling of Environmental Chemicals that Inhibit the TGFβ/SMAD Signaling Pathway. Chem. Res. Toxicol. 32, 2433–2444. doi:10.1021/acs.chemrestox.9b00228
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. (1994). Mechanism of Activation of the TGF-β Receptor. Nature 370, 341–347. doi:10.1038/370341a0
Xu, H., Gu, S., Riquelme, M. A., Burra, S., Callaway, D., Cheng, H., et al. (2015). Connexin 43 Channels Are Essential for Normal Bone Structure and Osteocyte Viability. J. Bone Miner. Res. 30, 436–448. doi:10.1002/jbmr.2374
Xu, X. L., Dai, K. R., and Tang, T. T. (2003). [The Role of Smads and Related Transcription Factors in the Signal Transduction of Bone Morphogenetic Protein Inducing Bone Formation]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 17, 359–362.
Yan, T., Riggs, B. L., Boyle, W. J., and Khosla, S. (2001). Regulation of Osteoclastogenesis and RANK Expression by TGF-?1. J. Cel. Biochem. 83, 320–325. doi:10.1002/jcb.1200
Yang, D., Okamura, H., Nakashima, Y., and Haneji, T. (2013). Histone Demethylase Jmjd3 Regulates Osteoblast Differentiation via Transcription Factors Runx2 and Osterix. J. Biol. Chem. 288, 33530–33541. doi:10.1074/jbc.M113.497040
Yang, J. H., Kim, S. C., Kim, K. M., Jang, C. H., Cho, S. S., Kim, S. J., et al. (2016a). Isorhamnetin Attenuates Liver Fibrosis by Inhibiting TGF-β/Smad Signaling and Relieving Oxidative Stress. Eur. J. Pharmacol. 783, 92–102. doi:10.1016/j.ejphar.2016.04.042
Yang, S., and Duan, X. (2016). Epigenetics, Bone Remodeling and Osteoporosis. Curr. Stem Cel Res Ther.
Yang, X., Huo, H., Xiu, C., Song, M., Han, Y., Li, Y., et al. (2016b). Inhibition of Osteoblast Differentiation by Aluminum Trichloride Exposure Is Associated with Inhibition of BMP-2/Smad Pathway Component Expression. Food Chem. Toxicol. 97, 120–126. doi:10.1016/j.fct.2016.09.004
Yasui, T., Kadono, Y., Nakamura, M., Oshima, Y., Matsumoto, T., Masuda, H., et al. (2011). Regulation of RANKL-Induced Osteoclastogenesis by TGF-β through Molecular Interaction between Smad3 and Traf6. J. Bone Miner Res. 26, 1447–1456. doi:10.1002/jbmr.357
Yoshikawa, Y., Yoshizawa, T., Domae, E., Hieda, Y., Takeyama, A., Hirota, S., et al. (2015). RNA Interference-Mediated Knockdown of Smad1 Inhibits Receptor Activator of Nuclear Factor κB Ligand Expression Induced by BMP-2 in Primary Osteoblasts. Arch. Oral Biol. 60, 1319–1326. doi:10.1016/j.archoralbio.2015.06.001
Zanotti, S., Smerdel‐Ramoya, A., Stadmeyer, L., and Canalis, E. (2008). Activation of the ERK Pathway in Osteoblastic Cells, Role of Gremlin and BMP‐2. J. Cel. Biochem. 104, 1421–1426. doi:10.1002/jcb.21715
Zhang, J., Zhang, X., Xie, F., Zhang, Z., van Dam, H., Zhang, L., et al. (2014). The Regulation of TGF-β/SMAD Signaling by Protein Deubiquitination. Protein Cell 5 (7), 503–517. doi:10.1007/s13238-014-0058-8
Zhang, Q., Chang, X., Wang, H., Liu, Y., Wang, X., Wu, M., et al. (2020). TGF‐β1 Mediated Smad Signaling Pathway and EMT in Hepatic Fibrosis Induced by Nano NiO In Vivo and In Vitro. Environ. Toxicol. 35, 419–429. doi:10.1002/tox.22878
Zhang, X., Zhang, P., Shao, M., Zang, X., Zhang, J., Mao, F., et al. (2018). SALL4 Activates TGF-β/SMAD Signaling Pathway to Induce EMT and Promote Gastric Cancer Metastasis. Cmar 10, 4459–4470. doi:10.2147/CMAR.S177373
Keywords: transforming growth factor-β, bone morphogenetic proteins, bone remodeling, osteoporosis, Smad signaling pathway
Citation: Zou M-L, Chen Z-H, Teng Y-Y, Liu S-Y, Jia Y, Zhang K-W, Sun Z-L, Wu J-J, Yuan Z-D, Feng Y, Li X, Xu R-S and Yuan F-L (2021) The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies. Front. Mol. Biosci. 8:593310. doi: 10.3389/fmolb.2021.593310
Received: 10 August 2020; Accepted: 23 April 2021;
Published: 05 May 2021.
Edited by:
Manuel Izquierdo, Consejo Superior de Investigaciones Científicas (CSIC), SpainReviewed by:
Danilo Swann Matassa, University of Naples Federico II, ItalyTeresita Padilla-Benavides, Wesleyan University, United States
Copyright © 2021 Zou, Chen, Teng, Liu, Jia, Zhang, Sun, Wu, Yuan, Feng, Li, Xu and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xia Li, lixia.ahmu.cn@163.com; Rui-Sheng Xu, xuruisheng@medmail.com.cn; Feng-Lai Yuan, bjjq88@jiangnan.edu.cn
†These authors have contributed equally to this work